Jarrett Jennifer
SEC CIK 1671311 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | See Remarks, Dir | 500.0K | — | — | 1 | 2026-03-30 | 2026-03-30 |
| SNDX | Syndax Pharmaceuticals Inc | Dir | 114.0K | — | — | 5 | 2022-02-02 | 2026-02-04 |
| RCUS | Arcus Biosciences, Inc. | COO, Dir | 224.0K | — | $11.23M | 32 | 2021-09-20 | 2026-01-23 |
| SRZN | Surrozen, Inc./DE | Former Dir | 30.0K | — | — | 1 | 2021-08-11 | 2021-08-11 |
Most active insiders at DMRA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schambye Hans T. | CEO, Dir | — | $15.0K |
| 2 | Winslow Garrett | GC | — | $12.8K |
| 3 | Firmani Lori | CFO | — | $2,890 |
| 4 | Sattarzadeh Sherwin | COO | — | — |
| 5 | Bruno Julianne | Dir | — | — |
| 6 | Hewes L. Becker | Chief Medical Off | — | — |
| 7 | Fairmount Healthcare Fund II L.P. | 10% | — | — |
| 8 | Jarrett Jennifer | See Remarks, Dir | — | — |
Transactions 39
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-01 17:30 | 2026-03-30 | DMRA | Damora Therapeutics, Inc. | Jarrett Jennifer | See Remarks, Dir | A - Grant | $0.00 | +500.0K | 500.0K | New | $0 |
| 2026-02-06 | 2026-02-04 | SNDX | Syndax Pharmaceuticals Inc | Jarrett Jennifer | Dir | A - Grant | $0.00 | +24.0K | 114.0K | +27% | $0 | |
| D | 2026-01-26 | 2026-01-23 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | A - Grant | $0.00 | +31.0K | 224.0K | +16% | $0 |
| M | 2025-12-18 | 2025-12-16+ | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale | $22.01 | -21.2K | 203.0K | -9% | -$466.8K |
| D | 2025-11-12 | 2025-11-07 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale+OE | $18.97 | -50.3K | 214.2K | -19% | -$954.0K |
| D | 2025-11-12 | 2025-11-07 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | M - OptEx | $1.23 | +50.3K | 264.5K | +23% | +$61.9K |
| DM | 2025-10-08 | 2025-10-06+ | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | M - OptEx | $1.23 | +50.3K | 226.7K | +29% | +$61.9K |
| DM | 2025-10-08 | 2025-10-06+ | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale+OE | $14.92 | -50.3K | 214.2K | -19% | -$750.5K |
| 2025-02-07 | 2025-02-05 | SNDX | Syndax Pharmaceuticals Inc | Jarrett Jennifer | Dir | A - Grant | $0.00 | +25.0K | 90.0K | +38% | $0 | |
| D | 2025-01-27 | 2025-01-23 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | A - Grant | $0.00 | +50.0K | 213.4K | +31% | $0 |
| 2024-12-17 | 2024-12-15 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | F - Tax | $16.08 | -27.5K | 163.4K | -14% | -$442.2K | |
| 2024-09-17 | 2024-09-15 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | F - Tax | $17.95 | -12.7K | 190.4K | -6% | -$227.4K | |
| 2024-06-18 | 2024-06-15 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | F - Tax | $16.97 | -12.7K | 203.1K | -6% | -$215.0K | |
| 2024-03-29 | 2024-03-27 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale | $17.55 | -11.6K | 215.3K | -5% | -$202.7K | |
| M | 2024-03-20 | 2024-03-18 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale | $17.92 | -13.4K | 228.1K | -6% | -$240.9K |
| M | 2024-02-28 | 2024-02-26+ | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale | $20.09 | -58.6K | 274.3K | -18% | -$1.18M |
| 2024-02-09 | 2024-02-07 | SNDX | Syndax Pharmaceuticals Inc | Jarrett Jennifer | Dir | A - Grant | $0.00 | +17.0K | 65.0K | +35% | $0 | |
| D | 2024-01-25 | 2024-01-23 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | A - Grant | $0.00 | +40.0K | 298.9K | +15% | $0 |
| 2023-12-26 | 2023-12-22 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $17.76 | -21.5K | 258.9K | -8% | -$382.2K | |
| M | 2023-12-20 | 2023-12-18+ | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | D - Sale to Iss | $17.92 | -22.7K | 280.4K | -8% | -$407.5K |
| 2023-09-26 | 2023-09-22 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $19.99 | -21.4K | 302.7K | -7% | -$427.2K | |
| 2023-09-20 | 2023-09-18 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | D - Sale to Iss | $20.40 | -12.5K | 324.1K | -4% | -$255.1K | |
| 2023-07-31 | 2023-07-28 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $20.25 | -45.0K | 336.6K | -12% | -$911.2K | |
| 2023-06-26 | 2023-06-22 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $19.12 | -12.4K | 381.6K | -3% | -$237.8K | |
| 2023-06-16 | 2023-06-16 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $19.35 | -12.6K | 394.0K | -3% | -$243.1K | |
| 2023-03-20 | 2023-03-16 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $16.81 | -8,729 | 406.2K | -2% | -$146.7K | |
| 2023-02-03 | 2023-02-02 | SNDX | Syndax Pharmaceuticals Inc | Jarrett Jennifer | Dir | A - Grant | $0.00 | +16.0K | 48.0K | +50% | $0 | |
| M | 2023-01-30 | 2023-01-26+ | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $23.53 | -1,900 | 416.5K | -0.5% | -$44.7K |
| D | 2023-01-25 | 2023-01-23 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | A - Grant | $0.00 | +45.8K | 416.8K | +12% | $0 |
| M | 2022-12-16 | 2022-12-16 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $30.75 | -16.5K | 150.2K | -10% | -$506.8K |
| 2022-09-20 | 2022-09-16 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $26.28 | -12.7K | 130.9K | -9% | -$333.2K | |
| M | 2022-06-21 | 2022-06-16+ | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $21.45 | -12.7K | 125.2K | -9% | -$272.3K |
| 2022-03-18 | 2022-03-16 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $31.62 | -9,617 | 106.0K | -8% | -$304.1K | |
| D | 2022-03-10 | 2022-03-08 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | A - Grant | $0.00 | +31.2K | 121.8K | +34% | $0 |
| 2022-02-03 | 2022-02-02 | SNDX | Syndax Pharmaceuticals Inc | Jarrett Jennifer | Dir | A - Grant | $0.00 | +16.0K | 32.0K | +100% | $0 | |
| M | 2021-12-22 | 2021-12-20 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $41.48 | -34.8K | 114.3K | -23% | -$1.44M |
| M | 2021-12-20 | 2021-12-16+ | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $40.12 | -12.7K | 131.0K | -9% | -$508.7K |
| M | 2021-09-22 | 2021-09-20+ | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO, Dir | S - Sale | $35.35 | -47.5K | 112.8K | -30% | -$1.68M |
| D | 2021-08-13 | 2021-08-11 | SRZN | Surrozen, Inc./DE | Jarrett Jennifer | Former Dir | A - Grant | — | +30.0K | 30.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations